| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥660.6B | ¥618.3B | +6.8% |
| Operating Income | ¥32.6B | ¥31.0B | +5.3% |
| Ordinary Income | ¥36.2B | ¥37.1B | -2.5% |
| Net Income | ¥23.7B | ¥25.7B | -7.6% |
| ROE | 4.3% | 4.9% | - |
FY2026 Q3 cumulative results: Revenue 66.06B yen (YoY +6.8%), Operating Income 3.26B yen (YoY +5.3%), Ordinary Income 3.62B yen (YoY -2.5%), Net Income 2.37B yen (YoY -7.6%). Revenue growth remained steady, expanding from 61.83B yen in the prior year period, while operating income increased modestly from 3.10B yen. However, net income declined from 2.57B yen, pressured by extraordinary losses totaling 1.04B yen including restructuring costs. Operating margin stood at 4.9%, below industry standards, while net margin compressed to 3.6% from 4.2% in the prior year. Total assets expanded to 83.82B yen from 76.28B yen, supported by equity of 55.71B yen versus 52.03B yen previously. The results reflect a pattern of revenue growth with declining net profitability, driven by one-time charges and working capital efficiency challenges.
Revenue increased 4.23B yen or 6.8% YoY to 66.06B yen, driven by balanced growth across geographic markets. By segment, VCCS generated 41.52B yen (down 0.7% from 41.79B yen), CTC achieved 14.39B yen (up 25.7% from 11.44B yen), and FC-MD recorded 8.30B yen (down 0.9% from 8.38B yen), while the Incubation Center segment expanded significantly to 1.85B yen from 0.22B yen driven by the acquisition of network solution business from Koha Co. via company split. Geographically, Japan grew 14.9% to 21.67B yen, Americas increased 4.9% to 25.47B yen, and Asia expanded 1.2% to 18.93B yen. On the profit side, operating income rose 5.3% to 3.26B yen from 3.10B yen, yielding an operating margin of 4.9% versus 5.0% in the prior year, indicating limited margin expansion despite revenue growth. Gross profit was 12.79B yen with a gross margin of 19.4%, constrained by cost pressures. Selling, general and administrative expenses totaled 9.53B yen. Ordinary income declined 2.5% to 3.62B yen despite operating income growth, as non-operating income net contribution of 0.36B yen (comprising foreign exchange gains of 0.23B yen and dividend income among other items) partially offset by increased expenses. The gap between ordinary income and net income widened materially, with net income falling 7.6% to 2.37B yen, representing a 34.4% difference versus ordinary income. This divergence stems from extraordinary losses totaling 1.04B yen, including restructuring costs of approximately 0.93B yen, offset partially by a gain on negative goodwill of 0.31B yen from the Incubation Center business acquisition. The pattern observed is revenue growth with profit decline, as top-line expansion was insufficient to offset margin compression and one-time charges affecting bottom-line profitability.
By segment operating profit, VCCS generated 1.55B yen (down 26.1% from 2.09B yen), representing the largest segment but experiencing significant profit contraction despite maintaining revenue scale. CTC delivered 2.05B yen (up 113.2% from 0.96B yen), emerging as the strongest profit contributor with both revenue and margin expansion. FC-MD recorded 0.27B yen (down 58.8% from 0.65B yen), showing substantial profit deterioration alongside flat revenue. The Incubation Center segment posted a loss of 0.63B yen (expanded from 0.62B yen loss), reflecting ongoing investment phase despite revenue expansion from the acquired business. VCCS remains the core business by revenue share at 62.9% of total segment revenue, though its profit contribution has diminished. Segment margin differences are material, with CTC achieving approximately 14.2% operating margin, while VCCS margin compressed to 3.7%, FC-MD to 3.2%, and Incubation Center remaining loss-making. The profit mix shift toward CTC and away from VCCS represents a structural change in earnings composition.
[Profitability] ROE of 4.2% declined from prior levels and sits below the industry median of 5.2%, while operating margin of 4.9% trails the industry median of 8.7% significantly. Net profit margin of 3.6% compares to industry median of 6.4%, indicating room for improvement in converting revenue to bottom-line profit. [Cash Quality] Cash and deposits of 17.44B yen provide coverage of 4.16 times against short-term debt of 4.19B yen, demonstrating adequate liquidity. [Investment Efficiency] Asset turnover of 0.79 exceeds the industry median of 0.58, suggesting relatively effective asset utilization despite working capital challenges. Return on assets of 2.8% falls below the industry median of 3.3%. [Financial Health] Current ratio of 221.7% and quick ratio of 184.3% indicate strong short-term solvency. Debt-to-equity ratio of 0.50 remains conservative, while interest coverage of 24.4 times confirms comfortable debt servicing capacity. Short-term debt represents 72.4% of total borrowings, warranting attention to refinancing structure.
Cash and deposits increased 4.12B yen YoY to 17.44B yen, indicating accumulation despite net income of 2.37B yen. Working capital movements show accounts receivable rising to 17.20B yen from 15.85B yen, reflecting 94 days sales outstanding that exceeds the industry median of 83 days and suggests collection efficiency challenges. Inventory expanded to 20.05B yen from 18.12B yen, representing 110 days inventory outstanding versus industry median of 109 days, pointing to elevated stock levels. Accounts payable increased substantially to 8.14B yen from 6.14B yen, indicating 47 days payables outstanding and suggesting extended payment terms being utilized for working capital management. The cash conversion cycle of 157 days exceeds the industry median range and reflects the combined pressure of slower collections and higher inventory. Long-term debt decreased 15.00B yen to 1.60B yen, representing debt repayment activity. The balance sheet expansion with total assets growing 9.9% to 83.82B yen was funded by retained earnings and working capital adjustments rather than significant new borrowing.
Ordinary income of 3.62B yen versus operating income of 3.26B yen reflects non-operating net contribution of approximately 0.36B yen. This comprises foreign exchange gains of 0.23B yen, dividend income, and interest income as primary components, partially offset by interest expenses of 0.13B yen. Non-operating income represents approximately 0.5% of revenue, consisting primarily of financial items rather than core operations. The divergence to net income highlights extraordinary loss impact of 1.04B yen, including restructuring costs that represent non-recurring factors, offset by the gain on negative goodwill of 0.31B yen from the business acquisition in the Incubation Center segment. While cash flow statement details are unavailable for quarterly reporting, the expansion of working capital balances relative to revenue growth suggests operating cash conversion may lag reported earnings. Receivables and inventory growth outpacing revenue increase by 8.5% and 10.6% respectively versus 6.8% revenue growth indicates potential earnings quality concerns from working capital absorption. The operating margin compression alongside revenue growth further suggests limited cash-backed profitability expansion.
Progress against full-year guidance shows revenue achievement of 74.2% (66.06B yen actual versus 89.00B yen forecast), operating income at 72.6% (3.26B yen versus 4.50B yen forecast), ordinary income at 77.8% (3.62B yen versus 4.65B yen forecast), and net income at 78.9% (2.37B yen versus 3.00B yen forecast) through Q3. All metrics track behind the standard 75% Q3 progress rate, with revenue showing the largest gap at negative 0.8 percentage points. Operating income progress lags by 2.4 percentage points, suggesting modest shortfall risk for the full year. The company maintains its full-year revenue growth guidance of 7.4% YoY and operating income growth of 6.5%, with ordinary income expected to increase 18.4%. The more aggressive ordinary income growth assumption of 18.4% versus operating income growth of 6.5% implies significant non-operating income contribution expectations in Q4. Given Q3 actual performance and one-time charges already recognized, achieving the net income target of 3.00B yen requires 0.63B yen in Q4, representing a 52% increase from Q3 run-rate, which may prove challenging without extraordinary gains or significant operational improvement.
Annual dividend of 48.0 yen per share consists of 24.0 yen interim and 24.0 yen year-end, though full-year forecast indicates 27.0 yen per share, requiring reconciliation. Based on net income of 2.37B yen and assuming the current 48.0 yen total payout, the payout ratio calculates to approximately 48.5% versus reported earnings. Compared to the prior year, dividend information shows stability in payout policy. The payout ratio remains within sustainable range below 60%, though cash flow coverage confirmation is limited by unavailable free cash flow data. Share buyback activity is not disclosed for the period. Assuming full-year net income guidance of 3.00B yen materializes with 27.0 yen per share dividend as forecasted, the prospective payout ratio would moderate to approximately 35%, providing conservative dividend coverage and room for potential payout expansion if earnings targets are achieved.
Working capital efficiency deterioration poses execution risk, with receivables growing faster than sales at 94 days outstanding versus 83 days industry median, and inventory levels elevated at 110 days versus 109 days industry median, resulting in a 157-day cash conversion cycle that absorbs significant operating cash and may pressure liquidity if trends persist. Refinancing risk emerges from debt structure concentration, with 72.4% of total borrowings maturing within one year totaling 4.19B yen against long-term debt of only 1.60B yen, requiring management attention to funding continuity despite adequate current cash coverage of 4.16 times. Profitability pressure from margin compression remains material, with operating margin of 4.9% significantly below the 8.7% industry median and net margin of 3.6% trailing the 6.4% industry median, indicating structural cost challenges or competitive pricing pressure that limits earnings expansion relative to revenue growth and may impact return ratios if unaddressed.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 4.2% underperforms industry median of 5.2% (manufacturing sector, N=100). Operating margin of 4.9% falls notably below industry median of 8.7%, positioning in the lower quartile and indicating significant margin improvement opportunity. Net profit margin of 3.6% compares to industry median of 6.4%, reflecting bottom-line conversion challenges.
Financial Health: Current ratio of 221.7% exceeds industry median of 283%, while remaining within healthy range. Debt-to-equity ratio of 0.50 indicates conservative leverage relative to industry capital structures. Short-term debt concentration at 72.4% of total borrowings represents above-average refinancing exposure.
Efficiency: Asset turnover of 0.79 surpasses industry median of 0.58, demonstrating superior asset productivity. However, receivables turnover at 94 days exceeds industry median of 83 days, inventory days of 110 align closely with median of 109 days, and payables days of 47 fall below median of 56 days, resulting in working capital cycle of 157 days that exceeds industry median of 108 days by 45%, indicating material inefficiency.
Growth: Revenue growth of 6.8% outpaces industry median of 2.8%, positioning in the upper quartile for top-line expansion, though this has not translated to proportionate profit growth given margin compression.
(Industry: Manufacturing, N=100 companies, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Revenue momentum remains positive with 6.8% YoY growth outpacing the 2.8% industry median, supported by balanced geographic diversification and significant expansion in the CTC segment up 25.7% and Incubation Center transformation, though this top-line strength has not translated to proportionate profit expansion given operating margin compression to 4.9% from 5.0% and net margin decline to 3.6% from 4.2%, highlighting the need for operational efficiency initiatives to restore profitability commensurate with revenue scale.
Structural earnings shift observed as CTC segment operating profit surged 113.2% to become the primary profit contributor at 2.05B yen with approximately 14.2% margin, while core VCCS segment profit contracted 26.1% to 1.55B yen with margin compressing to 3.7%, indicating a strategic rebalancing away from traditional business toward higher-margin operations, though successful execution of the Incubation Center turnaround remains critical given ongoing 0.63B yen losses despite revenue injection from acquisitions.
Working capital management deterioration presents a key operational challenge, with the cash conversion cycle extending to 157 days versus 108 days industry median, driven by receivables growth of 8.5% and inventory expansion of 10.6% both exceeding 6.8% revenue growth, absorbing cash that could otherwise support shareholder returns or debt reduction, while the 32.6% increase in payables to 8.14B yen from 6.14B yen suggests reliance on extended supplier payment terms to offset working capital pressure, requiring focused management attention to restore balance sheet efficiency and support sustainable cash generation.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.